# Hypertension (HTN) - Comprehensive Management Guideline

## Classification (ACC/AHA 2017)

| Category | Systolic (mmHg) | Diastolic (mmHg) |
|----------|-----------------|-------------------|
| Normal | < 120 | < 80 |
| Elevated | 120-129 | < 80 |
| Stage 1 HTN | 130-139 | 80-89 |
| Stage 2 HTN | >= 140 | >= 90 |
| Hypertensive Crisis | > 180 | > 120 |

## Blood Pressure Measurement

- Use validated, calibrated device with appropriately sized cuff
- Patient seated quietly for 5 minutes, feet on floor, arm supported at heart level
- Average of 2-3 readings on 2-3 separate occasions for diagnosis
- Ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) recommended to confirm diagnosis and exclude white-coat hypertension
- Rule out pseudohypertension in elderly (Osler maneuver)

## Blood Pressure Targets

- **General population**: < 130/80 mmHg
- **Patients >= 65 years**: SBP < 130 mmHg if tolerated (avoid < 120 in frail elderly)
- **Diabetes mellitus**: < 130/80 mmHg
- **Chronic kidney disease**: < 130/80 mmHg
- **Post-stroke**: < 130/80 mmHg (after initial acute phase)
- **Pregnancy**: See separate guideline; generally < 140/90; < 135/85 if on therapy

## Lifestyle Modifications (All Stages)

- **DASH diet**: Rich in fruits, vegetables, whole grains, low-fat dairy; reduced saturated fat
- **Sodium restriction**: < 1500 mg/day ideal; < 2300 mg/day minimum goal (approximately 5-6 mmHg SBP reduction)
- **Physical activity**: 150 minutes/week moderate-intensity aerobic exercise (approximately 5-8 mmHg reduction)
- **Weight loss**: Target BMI 18.5-24.9; each 1 kg loss reduces SBP by approximately 1 mmHg
- **Alcohol moderation**: <= 2 drinks/day (men), <= 1 drink/day (women) (approximately 4 mmHg reduction)
- **Smoking cessation**: Reduces overall cardiovascular risk; modest direct effect on BP
- **Potassium intake**: 3500-5000 mg/day through diet (unless CKD with hyperkalemia risk)

## When to Initiate Pharmacotherapy

- **Elevated BP (120-129/<80)**: Lifestyle modifications only
- **Stage 1 HTN with 10-year ASCVD risk < 10%**: Lifestyle modifications; reassess in 3-6 months
- **Stage 1 HTN with 10-year ASCVD risk >= 10%, or with diabetes, CKD, or known CVD**: Lifestyle + single antihypertensive agent
- **Stage 2 HTN**: Lifestyle + two first-line agents from different classes

## First-Line Antihypertensive Agents

### ACE Inhibitors (ACEi)
- Examples: lisinopril 10-40 mg, enalapril 5-40 mg, ramipril 2.5-20 mg
- Preferred in: diabetes, CKD with proteinuria, post-MI, HFrEF
- Side effects: dry cough (10-15%), hyperkalemia, angioedema (contraindication to rechallenge)
- Contraindicated in pregnancy (all trimesters), bilateral renal artery stenosis

### Angiotensin II Receptor Blockers (ARBs)
- Examples: losartan 50-100 mg, valsartan 80-320 mg, irbesartan 150-300 mg
- Use when ACEi not tolerated (cough)
- Similar contraindications to ACEi; do NOT combine ACEi + ARB

### Calcium Channel Blockers (CCBs)
- **Dihydropyridine**: amlodipine 2.5-10 mg, nifedipine ER 30-90 mg
- **Non-dihydropyridine**: diltiazem ER 120-360 mg, verapamil ER 120-480 mg
- Preferred in: African American patients, isolated systolic HTN in elderly
- Avoid non-DHP CCBs with beta-blockers (risk of bradycardia/heart block)

### Thiazide/Thiazide-like Diuretics
- Chlorthalidone 12.5-25 mg (preferred; longer half-life), hydrochlorothiazide 12.5-50 mg, indapamide 1.25-2.5 mg
- Preferred in: elderly, isolated systolic HTN, African American patients
- Monitor: electrolytes (hypokalemia, hyponatremia), uric acid, glucose

## Special Populations

### Chronic Kidney Disease
- ACEi or ARB first-line (especially with proteinuria; UACR > 300 mg/g)
- Add dihydropyridine CCB or diuretic as second agent (loop diuretic if eGFR < 30)
- Monitor potassium and creatinine within 2-4 weeks of ACEi/ARB initiation
- Tolerate up to 30% rise in creatinine after ACEi/ARB initiation

### Diabetes Mellitus
- ACEi or ARB preferred first-line (renoprotective)
- CCB or thiazide diuretic as add-on
- Avoid beta-blockers as first-line (mask hypoglycemia, metabolic effects) unless compelling indication

### Pregnancy
- **Safe agents**: labetalol, nifedipine ER, methyldopa
- **Contraindicated**: ACEi, ARBs, direct renin inhibitors, nitroprusside
- Target: < 140/90 mmHg (ACOG); some guidelines suggest < 135/85 mmHg

### African American Patients
- CCBs or thiazide diuretics preferred as initial therapy (stronger BP response)
- ACEi/ARBs still indicated when compelling indications present (diabetes with proteinuria, HFrEF)

## Resistant Hypertension

Defined as BP above goal despite 3 optimally dosed antihypertensives (including a diuretic), or requiring 4 or more agents.

### Workup
- Confirm adherence (pill counts, pharmacy records, directly observed therapy)
- Exclude white-coat effect with ABPM or HBPM
- Assess for secondary causes: primary aldosteronism (aldosterone/renin ratio), renal artery stenosis (renal duplex ultrasound), pheochromocytoma (plasma metanephrines), Cushing syndrome, OSA, thyroid disease, coarctation of aorta
- Review medications that raise BP: NSAIDs, oral contraceptives, decongestants, stimulants, corticosteroids

### Management
- Optimize diuretic therapy: switch to chlorthalidone if on HCTZ; add loop diuretic if eGFR < 30
- **Fourth-line agent**: spironolactone 25-50 mg/day (strongest evidence for resistant HTN)
- Alternative fourth-line agents: eplerenone, amiloride, beta-blocker, alpha-blocker, clonidine, hydralazine, minoxidil
